SectorBiotechnology Ⅲ
Established Date16/08/2013
Listing Date30/07/2020
ExchangeNASDAQ Stock Exchange
Full-time Employees20
Fiscal Year Ends31/12
Security TypeCommon stock
Office address400 Connell Drive, Suite 5500, Berkeley Heights, New Jersey
BusinessDevelops allogeneic T cell therapies.
IntroductionKalaris Therapeutics, Inc., established on August 16, 2013, is a Delaware limited liability company. The Company is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for common retinal diseases with serious unmet medical needs. The Company is developing TH103, a novel clinical-stage anti-vascular endothelial growth factor (" VEGF ") drug specifically designed to achieve prolonged intraocular retention and enhanced VEGF inhibition in patients with exudative and neovascular retinal diseases.
